OncoCyte will present the figures for the quarter ended on December 31, 2022 on April 3, 2023.
On average, 5 analysts expect earnings per share of -0.094 USD. That would represent a gain of 75.90 percent compared to last year, when -$0.390 was generated.
In terms of sales, a total of 5 analysts expect an average drop of 60.45 percent to USD 1.4 million. In the prior-year quarter, OncoCyte still had sales of $3.6 million.
At the end of the most recent fiscal year, the average estimate of 5 analysts was -$0.359 per share, compared to -$0.720 per share in the prior period. On the revenue side, 5 analysts are forecasting an average of $5.9 million after generating $7.7 million in the prior fiscal year period.
Editorial office finanzen.net
Leverage must be between 2 and 20
No data
